Streetbeat News

Stock Prices

BMY

Deep-pocketed investors are showing significant interest in Bristol-Myers Squibb (NYSE:BMY), with a notable increase in options activity. The sentiment is mixed, with 54% bullish and 45% bearish. Analysts have mixed ratings, with price targets ranging from $41 to $53.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:16 pm

DDOG

Investors with significant capital have taken a bullish stance on Datadog (NASDAQ:DDOG), as evidenced by recent options trading activity. Benzinga's options scanner identified 18 trades, with 72% being bullish. The expected price range for DDOG is between $102.0 and $120.0 over the next three months. Analysts have mixed ratings, with an average target price of $144.6.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:16 pm

AAPL

Financial giants have shown a bullish trend in Apple (NASDAQ:AAPL) options trading, with 47 unusual trades identified. 46% of traders were bullish, while 42% were bearish. Significant trades include both puts and calls, with a focus on a price band between $70.0 and $240.0. The average open interest for Apple options is 12,278.3, with a total volume of 695,827.00. Expert opinions on Apple remain positive, with target prices ranging from $186 to $285.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:16 pm

MSFT

PLTR

Palantir Technologies (PLTR) shares are rising following strong earnings and a new partnership with Microsoft (MSFT). The company reported better-than-expected EPS and sales, and the partnership aims to enhance data analytics and AI services for the U.S. Defense and Intelligence Community.

Portfolio Pulse from Dylan Berman

August 16, 2024 | 5:14 pm

DRUG

Bright Minds Biosciences Inc. (NASDAQ:DRUG) reported a significant reduction in net losses for Q3 2024, driven by the timing of program starts and completions within their drug portfolio. The company holds $6.2 million in cash and raised $900,000 through equity financing. Ongoing R&D efforts focus on 5-HT2C and 5-HT2A receptor agonists, with successful Phase 1 trials and preparatory work for Phase 2 studies. Despite progress, the company faces risks related to regulatory approvals, financing, and clinical trial uncertainties.

Portfolio Pulse from Juan Spínelli

August 16, 2024 | 5:11 pm

TGTX

Financial giants have shown a bullish stance on TG Therapeutics (NASDAQ:TGTX) with 62% of traders being bullish. The options market reveals significant trades, with a predicted price range of $15.0 to $20.0. The stock is currently trading at $22.04, up by 5.23%, and analysts have mixed ratings with price targets ranging from $20 to $49.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:03 pm

ULTA

The options market for Ulta Beauty (NASDAQ: ULTA) shows a bullish trend with 63% of trades being bullish. Major market movers are focusing on a price band between $330.0 and $450.0. Analysts have mixed ratings with price targets ranging from $325 to $500.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:02 pm

DHI

D.R. Horton (NYSE:DHI) has significantly outperformed the market over the past 15 years, delivering an average annual return of 19.2%. A $100 investment in DHI 15 years ago would be worth $1,395.26 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:02 pm

IDXX

IDEXX Laboratories (NASDAQ:IDXX) has significantly outperformed the market over the past 10 years, delivering an average annual return of 23.19%. A $100 investment in IDXX 10 years ago would be worth $788.94 today. The company's current market capitalization is $40.53 billion.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:02 pm

AMAT

AMZN

HD

CNBC's final trades include Amazon, Applied Materials, and Home Depot. These companies are highlighted for their potential investment opportunities.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 5:00 pm